Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

PURPOSE: The aims of this trial were to assess the safety and efficacy of two different dosing schedules of irinotecan (CPT-11) in recurrent glioma patients, to assess irinotecan pharmacokinetics in patients on enzyme-inducing antiepileptic drugs (EIAEDs) and steroids, and to correlate with toxicity...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Santisteban, Marta, Buckner, Jan C., Reid, Joel M., Wu, Wenting, Scheithauer, Bernd W., Ames, Matthew M., Felten, Sara J., Nikcevich, Daniel A., Wiesenfeld, Martin, Jaeckle, Kurt A., Galanis, Evanthia
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2008
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721337/
https://ncbi.nlm.nih.gov/pubmed/19066728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-008-9749-4
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg